etanidazole has been researched along with Cancer of Head in 24 studies
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.
etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to evaluate the efficacy and toxicity of Etanidazole, a hypoxic cell sensitizer, combined with radiotherapy in the treatment of head and neck squamous cell carcinoma." | 2.68 | Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas. ( Bey, P; Brisgand, D; Busutti, L; Chassagne, D; Chavaudra, J; Cionini, L; Eschwège, F; Guerra, M; Hill, C; Malaise, EP; N'Guyen, T; Romanini, A; Sancho-Garnier, H, 1997) |
| "To prospectively evaluate the pharmacokinetic monitoring and drug dose adjustment of Etanidazole (Eta) in patients treated on the RTOG randomized trial for Stage III and IV head and neck cancer." | 2.68 | Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial. ( Buswell, L; Coleman, CN; Lee, DJ; Noll, L; Pajak, TF; Riese, NE; Stetz, J, 1997) |
| "Etanidazole was given at a dose of 2 g/m2, 3 times per week, for a total of 30-34 g/m2." | 2.67 | First analysis of tumor regression for the European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. ( Charreau, I; Chassagne, D; Eschwege, F; Malaise, EP; Sancho-Garnier, H, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (58.33) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silvoniemi, A | 1 |
| Suilamo, S | 1 |
| Laitinen, T | 1 |
| Forsback, S | 2 |
| Löyttyniemi, E | 1 |
| Vaittinen, S | 1 |
| Saunavaara, V | 1 |
| Solin, O | 3 |
| Grönroos, TJ | 2 |
| Minn, H | 3 |
| Koch, CJ | 3 |
| Komar, G | 2 |
| Lehtiö, K | 1 |
| Seppänen, M | 2 |
| Eskola, O | 2 |
| Levola, H | 1 |
| Lindholm, P | 2 |
| Sipilä, H | 2 |
| Seppälä, J | 1 |
| Grénman, R | 1 |
| Aguilera, TA | 1 |
| Giaccia, AJ | 1 |
| Evans, SM | 3 |
| Glaholm, J | 1 |
| Watkinson, JC | 1 |
| Le, QT | 1 |
| Du, KL | 1 |
| Chalian, AA | 2 |
| Mick, R | 1 |
| Zhang, PJ | 1 |
| Hahn, SM | 1 |
| Quon, H | 1 |
| Lustig, R | 1 |
| Weinstein, GS | 1 |
| Lee, DJ | 7 |
| Fu, KK | 4 |
| Cooper, JS | 4 |
| Wasserman, TH | 3 |
| Cosmatos, D | 4 |
| Pajak, TF | 2 |
| Coleman, CN | 3 |
| Marcial, VA | 2 |
| Rotman, M | 2 |
| Ortiz, HG | 1 |
| Beitler, JJ | 1 |
| Abrams, RA | 1 |
| Curran, WJ | 1 |
| Brown, JM | 1 |
| Moini, M | 1 |
| Giuliano, J | 1 |
| Westra, WH | 1 |
| Cox, JD | 1 |
| Eschwège, F | 3 |
| Sancho-Garnier, H | 3 |
| Chassagne, D | 3 |
| Brisgand, D | 1 |
| Guerra, M | 1 |
| Malaise, EP | 3 |
| Bey, P | 1 |
| Busutti, L | 1 |
| Cionini, L | 1 |
| N'Guyen, T | 1 |
| Romanini, A | 1 |
| Chavaudra, J | 1 |
| Hill, C | 1 |
| Riese, NE | 1 |
| Buswell, L | 1 |
| Noll, L | 1 |
| Stetz, J | 2 |
| Lee, WR | 1 |
| Berkey, B | 2 |
| Marcial, V | 3 |
| Vikram, B | 1 |
| Coia, LR | 1 |
| Ortiz, H | 1 |
| Hahn, S | 1 |
| Pook, DR | 1 |
| Jenkins, WT | 1 |
| Zhang, P | 1 |
| Stevens, C | 1 |
| Weber, R | 1 |
| Weinstein, G | 1 |
| Benjamin, I | 1 |
| Mirza, N | 1 |
| Morgan, M | 1 |
| Rubin, S | 1 |
| McKenna, WG | 1 |
| Lord, EM | 1 |
| Phillips, TL | 1 |
| Davis, LW | 1 |
| Rubin, P | 1 |
| Charreau, I | 2 |
| Coleman, N | 1 |
| Phillips, T | 1 |
| Davis, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer[NCT01881451] | 5 participants (Actual) | Observational | 2013-08-31 | Terminated (stopped due to Due to slow accrual and access to the study drug.) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for etanidazole and Cancer of Head
| Article | Year |
|---|---|
Hypoxic sensitizer and cytotoxin for head and neck cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Hypoxia; Clinical Trials as Topic; Clinical Trials, | 1996 |
10 trials available for etanidazole and Cancer of Head
| Article | Year |
|---|---|
Repeatability of tumour hypoxia imaging using [
Topics: Aged; Etanidazole; Female; Fluorine Radioisotopes; Head and Neck Neoplasms; Humans; Hydrocarbons, Fl | 2018 |
Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas.
Topics: Carcinoma, Squamous Cell; Etanidazole; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; N | 1995 |
Results of a European randomized trial of Etanidazole combined with radiotherapy in head and neck carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Administration | 1997 |
Pharmacokinetic monitoring and dose modification of etanidazole in the RTOG 85-27 phase III head and neck trial.
Topics: Antineoplastic Agents; Area Under Curve; Disease-Free Survival; Etanidazole; Head and Neck Neoplasms | 1997 |
Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27.
Topics: Analysis of Variance; Anemia; Antineoplastic Agents; Carcinoma, Squamous Cell; Etanidazole; Female; | 1998 |
Detection of hypoxia in human squamous cell carcinoma by EF5 binding.
Topics: Adult; Aged; Antineoplastic Agents; Binding Sites; Carcinoma, Squamous Cell; Cell Hypoxia; Etanidazo | 2000 |
Logistics in designing clinical trials for etanidazole (SR 2508): an RTOG experience.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Etanidazole; Head and Neck Neoplasms; Humans; N | 1992 |
First analysis of tumor regression for the European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas.
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Etanidazole; Female; Head and Neck Neoplasms; H | 1992 |
Progress report of a phase II and a phase III trial with etanidazole (SR-2508): a multicentre European study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Evaluation | 1991 |
Clinical trials with etanidazole (SR-2508) by the Radiation Therapy Oncology Group (RTOG).
Topics: Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Evaluation; Etanidazole; Head and Neck Neo | 1991 |
13 other studies available for etanidazole and Cancer of Head
| Article | Year |
|---|---|
Invited editorial for the paper by Silvoniemi et al. "Repeatability of tumor hypoxia imaging using [
Topics: Etanidazole; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Positron Emission Tomography C | 2018 |
Prognostic value of tumour blood flow, [¹⁸F]EF5 and [¹⁸F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy.
Topics: Adult; Aged; Chemoradiotherapy; Etanidazole; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms | 2014 |
The end of the hypoxic EPOch.
Topics: Anemia; Blood Transfusion; Carcinoma, Squamous Cell; Cell Hypoxia; Clinical Trials as Topic; Erythro | 2015 |
18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer.
Topics: Adult; Aged; Carcinoma, Small Cell; Cell Hypoxia; Etanidazole; Female; Fluorine Radioisotopes; Head | 2008 |
Developments in radiotherapy and adjuvant chemotherapy for head and neck cancer.
Topics: Antineoplastic Agents; Cell Hypoxia; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose Fractio | 2003 |
Identifying and targeting hypoxia in head and neck cancer: a brief overview of current approaches.
Topics: Antigens, Neoplasm; Biomarkers; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Squamous Cell | 2007 |
Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome.
Topics: Aged; Carcinoma, Squamous Cell; Cell Hypoxia; Etanidazole; Female; Fluorescent Antibody Technique; H | 2007 |
End of an era or not? That is the question--in response to Dr. J. M. Brown, IJROBP 32:883-885; 1995.
Topics: Clinical Trials, Phase III as Topic; Etanidazole; Head and Neck Neoplasms; Humans; Oxygen Consumptio | 1995 |
Statistical response to Dr. J. M. Brown, IJROBP 32:883-885; 1995.
Topics: Etanidazole; Head and Neck Neoplasms; Humans; Neoplasm Staging; Probability; Randomized Controlled T | 1995 |
"Reports of my death [may be] greatly exaggerated" (adapted from Mark Twain)--in response to Dr. J. M. Brown, IJROBP 32:883-885; 1995.
Topics: Etanidazole; Head and Neck Neoplasms; Humans; Radiation-Sensitizing Agents; Randomized Controlled Tr | 1995 |
Hypoxic cell radiosensitizers: the end of an era? Regarding Lee et al., IJROBP 32:567-576; 1995.
Topics: Cell Hypoxia; Clinical Trials, Phase III as Topic; Etanidazole; Forecasting; Head and Neck Neoplasms | 1995 |
Clinical science and patient care: lessons from cooperative randomized clinical trials.
Topics: Carcinoma; Cell Hypoxia; Etanidazole; Head and Neck Neoplasms; Humans; Multicenter Studies as Topic; | 1997 |
Validation of the RTOG recursive partitioning classification for head and neck tumors.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Databases, Factual; Etanidazole; Head and Neck Neop | 2001 |